SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.61-0.6%Nov 6 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (6087)4/16/2002 5:24:18 PM
From: Archie Meeties  Read Replies (2) of 52153
 
The only comment to offer is that sensitivity and specificity are not the data you should be interested in. What you want to know is if early detection by seldi in those various cancers is early enough to influence treatment or change morbitidy/mortality. Even if the sensitivity was lower, if there was a remarkable diffrence in outcomes by early detection, the technology would be used.

Because they didn't say otherwise, you have to assume that the numbers you see are in patients already diagnosed with the various cancers. That's nothing to get excited about. If, on the otherhand, these patients had occult disease which was diagnosed by seldi prior to the usual clinical/radiographic diagnosis, that would be interesting (next step). It still wouldn't be useful unless early diagnosis could influence treatment (for example, diagnosis prior to metastases).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News